(Q36631420)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Apoptosis as a therapeutic tool in IBD? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Andreas Lügering

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Pia Lebiedz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Torsten Kucharzik

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

English

0 references

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

21 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

1072

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

62-77

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

The role of Th1/Th2 polarization in mucosal immunity

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

The immunology of mucosal models of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Update in inflammatory bowel disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Cell cycle- and activation-dependent regulation of cyclosporin A-induced T cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

FK 506-mediated T-cell apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

The TNF and TNF receptor superfamilies: integrating mammalian biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Tumor necrosis factor: an apoptosis JuNKie?

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

The phosphodiesterase inhibitor, pentoxifylline, alters rat intestinal epithelial cell proliferation via changes in the expression of transforming growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Thalidomide and its derivatives: emerging from the wilderness

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Cell death: critical control points

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Apoptosis as a therapeutic tool in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

MAP kinases in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1326.013

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1326.013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17057191%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference